Use of tiotropium in patients with COPD aged 80 years and older
- PMID: 23596463
- PMCID: PMC3627447
- DOI: 10.3892/etm.2013.956
Use of tiotropium in patients with COPD aged 80 years and older
Abstract
The purpose of this study was to examine clinical features and treatment modality approaches in patients with chronic obstructive pulmonary disease (COPD), particularly in those aged 80 years and older. Using databases available at Mito Kyodo General Hospital (Japan), the medical records of COPD patients between April 2009 and December 2011 were retrospectively reviewed. The patient population was divided into three age groups; less than 70 years (the <70 age group), between 70-79 years (the 70-79 age group) and 80 years or older (the ≥80 age group). Demographic data, as well as the efficacy and safety of tiotropium, were compared between the three groups. Patients in the ≥80 age group comprised 35.6% of the study population with COPD (n=174). The ≥80 and 70-79 age groups demonstrated a higher proportion of comorbid disease compared with the <70 age group. A subjective improvement of dyspnea on effort as well as no additional adverse effects were observed in the ≥80 age group, similar to the other two age groups. However, higher incidence of acute exacerbation of COPD in patients aged ≥80 years old was found, particularly in those with comorbid disease. The efficacy and safety of tiotropium in COPD patients in the ≥80 age group were almost identical to patients <80 years old, however, physicians must be cautious with acute exacerbation of COPD in the extremely elderly population with comorbid disease.
Keywords: chronic obstructive pulmonary disease; comorbid disease; elderly; octogenarian; tiotropium.
Similar articles
-
Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.Treat Respir Med. 2004;3(4):247-68. doi: 10.2165/00151829-200403040-00005. Treat Respir Med. 2004. PMID: 15350163 Review.
-
Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.Lancet Respir Med. 2013 Sep;1(7):524-33. doi: 10.1016/S2213-2600(13)70158-9. Epub 2013 Aug 21. Lancet Respir Med. 2013. PMID: 24461613 Clinical Trial.
-
Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease.Ann Am Thorac Soc. 2014 Nov;11(9):1351-61. doi: 10.1513/AnnalsATS.201404-174OC. Ann Am Thorac Soc. 2014. PMID: 25289942 Clinical Trial.
-
Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance.Int J Chron Obstruct Pulmon Dis. 2008;3(4):771-80. doi: 10.2147/copd.s3935. Int J Chron Obstruct Pulmon Dis. 2008. PMID: 19281092 Free PMC article. Clinical Trial.
-
Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease.Drugs. 2012 Jan 22;72(2):273-300. doi: 10.2165/11208620-000000000-00000. Drugs. 2012. PMID: 22217233 Review.
Cited by
-
Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age.Int J Chron Obstruct Pulmon Dis. 2016 Oct 31;11:2701-2710. doi: 10.2147/COPD.S108758. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27843306 Free PMC article.
-
Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.BMC Pulm Med. 2020 May 11;20(1):134. doi: 10.1186/s12890-020-1156-4. BMC Pulm Med. 2020. PMID: 32393215 Free PMC article. Clinical Trial.
-
Pharmacotherapies in Older Adults with COPD: Challenges and Opportunities.Drugs Aging. 2023 Jul;40(7):605-619. doi: 10.1007/s40266-023-01038-0. Epub 2023 Jun 14. Drugs Aging. 2023. PMID: 37316689 Free PMC article. Review.
-
Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies.NPJ Prim Care Respir Med. 2020 Dec 4;30(1):53. doi: 10.1038/s41533-020-00212-w. NPJ Prim Care Respir Med. 2020. PMID: 33277507 Free PMC article. Clinical Trial.
References
-
- Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765–773. - PubMed
-
- Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting broncho-dilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1136–1142. - PubMed
-
- Disse B, Speck GA, Rominger KL, Witek TJ, Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999;64:457–464. - PubMed
-
- Witek TJ, Souhrada JF, Serby CW, Disse B. Tiotropium (Ba679). Pharmacology and early clinical observations. In: Spector SS, editor. Anticholinergics in the Upper and Lower Airways. Marcel Dekker, Inc; New York, NY: 1999. pp. 137–152.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous